The new eyePlate-S

Same trusted plate, now with a smaller tube.

Less invasive tube insertion
Smaller lumen to limit hypotony

Surgical Treatment of Glaucoma

The eyeWatch

State of the art technology.

For your vision.

The eyePlate in numbers

Published data at 1 year follow-up¹

IOP reduction, while
preventing hypotony

Reduction in anti-glaucoma
drugs for patients

Corneal endothelial
cell loss

IOP reduction, while
preventing hypotony

Reduction in anti-glaucoma
drugs for patients

Corneal endothelial
cell loss

69%

IOP Reduction

Mean IOP was reduced from 35.7mmHg to 11.1mmHg at 1 year after the surgery

74%

Reduction in Medications

Medications were reduced in average from 3.5 to 0.85. 69% of patients were off drops after 1 year.

92%

Success Rate

Very high success rate, with 54% of patients having good IOP and completely off medication at 1 year (complete success)

Dr. Faisal Ahmed, The London Clinic, UK

“The eyePlate is a great glaucoma drainage device and it allows a microinvasive tube surgery (MITS) procedure I presented a few year ago in WGC. It is very atraumatic and I am pleased with the results.”

Success rate defined as ability to maintain IOP between 5-18mmHg after 1 year
Singh et al., Minimally Invasive Tube Surgery (MITS) – a novel method in glaucoma drainage device implantation, Journal of Clinical Medecine, 2024

Surgery videos

François, eyeWatch patient

“After numerous failed surgeries, I had an eyeWatch 2 years ago. I am finally off medications and my eye pressure has remained stable since. I am very happy with the results as I never had the need for a re-operation. “

Dr. Ike Ahmed

“Titration is the holy grail for glaucoma surgery, to provide an ability to adjust flow for individual patient needs at specific postoperative time points. The eyeWatch glaucoma shunt is a major step forward in protecting from early hypotony while allowing for added IOP reduction as needed. “